Hugo Ten Cate Selected Research

Hugo Ten Cate Research Topics

3	COVID-19 12/2023 - 01/2022
3	Thrombosis (Thrombus) 01/2022 - 12/2010
2	Venous Thromboembolism 10/2022 - 07/2021
2	Neoplasms (Cancer) 10/2022 - 12/2010
2	Thromboembolism 11/2018 - 01/2018
1	Venous Thrombosis (Deep-Vein Thrombosis) 12/2023
1	Inflammation (Inflammations) 12/2023
1	Thrombocytopenia (Thrombopenia) 01/2022
1	Atrial Fibrillation 11/2018
1	Heart Failure 11/2018
1	Hemorrhage 01/2018
1	Pulmonary Embolism 10/2012
1	Arterial Occlusive Diseases (Arterial Occlusive Disease) 01/2011
1	Atherosclerosis 01/2011
1	Thrombophilia 12/2010
1	Metabolic Syndrome (Dysmetabolic Syndrome X) 08/2004
1	Hypertriglyceridemia 08/2004
1	Familial Combined Hyperlipidemia (Combined Hyperlipidemia, Familial) 08/2004
1	Hyperinsulinism (Hyperinsulinemia) 08/2004

4	Vitamin K FDA Link 10/2022 - 01/2018
2	AnticoagulantsIBA 12/2023 - 10/2022
2	fibrin fragment D (D-dimer)IBA 01/2022 - 10/2012
1	coumarinIBA 12/2023
1	von Willebrand FactorIBA 01/2023
1	Thrombin FDA Link 01/2023
1	Fibrinogen (Factor I)FDA Link 01/2022
1	VaccinesIBA 01/2022
1	Biomarkers (Surrogate Marker)IBA 01/2022
1	4- ((1,4,8,11- tetraazacyclotetradec- 1- yl)methyl)benzoic acidIBA 07/2021
1	Prothrombin (Factor II)IBA 01/2018
1	ferric chlorideIBA 01/2011
1	CholesterolIBA 01/2011
1	HDL LipoproteinsIBA 01/2011
1	HDL CholesterolIBA 01/2011
1	Scavenger Receptors (Scavenger Receptor)IBA 01/2011
1	A-factor (Streptomyces)IBA 12/2010
1	ThrombomodulinIBA 08/2004
1	oxidized low density lipoproteinIBA 08/2004
1	LDL Lipoproteins (beta Lipoproteins)IBA 08/2004
1	Plasminogen Activator Inhibitor 1IBA 08/2004

1	Central Venous Catheters 12/2010